Oral Antibiotic Recommendations for Bacterial Peritonitis

Introduction to Treatment Guidelines

The American Association for the Study of Liver Diseases recommends oral ciprofloxacin 500 mg twice daily as the primary oral option for spontaneous bacterial peritonitis (SBP) in cirrhotic patients, after initial IV therapy 1
For secondary/community-acquired peritonitis, the Infectious Diseases Society of America recommends oral amoxicillin-clavulanate or oral ciprofloxacin plus metronidazole as the recommended regimens 2

Third-generation cephalosporins, such as cefotaxime 2g IV every 6-8 hours or ceftriaxone 1g IV every 12-24 hours, remain first-line for SBP, according to the American Association for the Study of Liver Diseases 1
Standard treatment duration for SBP is 5-10 days, with adjustments based on clinical response and susceptibility results, as recommended by the American Association for the Study of Liver Diseases 1

Oral amoxicillin-clavulanate 625 mg three times daily is the first-line oral option for community-acquired peritonitis without critical illness, providing coverage for both aerobic gram-negative bacteria and anaerobes, according to the Infectious Diseases Society of America 2
Alternative oral regimens include ciprofloxacin 500 mg twice daily plus metronidazole 500 mg three times daily for patients with beta-lactam allergies or intolerance, as recommended by the Infectious Diseases Society of America 2

Oral antibiotics should not be used as initial therapy for critically ill patients with septic shock or organ failure, hospital-acquired or postoperative peritonitis with risk of multidrug-resistant organisms, or patients who cannot tolerate oral intake or have impaired gastrointestinal absorption, according to the Infectious Diseases Society of America 2
After clinical improvement on IV therapy, transition to oral agents such as moxifloxacin 400 mg daily is appropriate, with clinical success rates of 80-82%, as recommended by the American Association for the Study of Liver Diseases 1

The treatment duration for SBP is 5-7 days total, including both IV and oral phases, according to the American Association for the Study of Liver Diseases 1
Clinical response should be evaluated within 48-72 hours of initiating therapy, and if no improvement is seen after 72 hours, alternative therapy, imaging for undrained collections, or resistant organisms should be considered, as recommended by the Infectious Diseases Society of America 4

Aminoglycosides, such as gentamicin, should not be used as oral therapy due to lack of oral bioavailability and poor anaerobic coverage, according to the Infectious Diseases Society of America 3
Local antibiotic susceptibility patterns should be reviewed before selecting empiric therapy to avoid resistance, as recommended by the Infectious Diseases Society of America 2